Cited by 1,844Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Functions of RANKL/RANK/OPG in bone modeling and remodeling

Open access

Boyce, Brendan F., Xing, Lianping·2008·Archives of Biochemistry and Biophysics

DOI 10.1016/j.abb.2008.03.018PMC PMC2413418

Open this paper in CoChat — free account

Abstract

The discovery of the RANKL/RANK/OPG system in the mid 1990s for the regulation of bone resorption has led to major advances in our understanding of how bone modeling and remodeling are regulated. It had been known for many years before this discovery that osteoblastic stromal cells regulated osteoclast formation, but it had not been anticipated that they would do this through expression of members of the TNF superfamily: receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG), or that these cytokines and signaling through receptor activator of NF-kappaB (RANK) would have extensive functions beyond regulation of bone remodeling. RANKL/RANK signaling regulates osteoclast formation, activation and survival in normal bone modeling and remodeling and in a variety of pathologic conditions characterized by increased bone turnover. OPG protects bone from excessive resorption by binding to RANKL and preventing it from binding to RANK. Thus, the relative concentration of RANKL and OPG in bone is a major determinant of bone mass and strength. Here, we review our current understanding of the role of the RANKL/RANK/OPG system in bone modeling and remodeling.

Integrity signals

Registry

Crossref · 10.1016/j.abb.2008.03.018

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246
Targeted Disruption of Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80258-5 · Cited by 4,244
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes
Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., & Werb, Z. (1998) · Cell · doi:10.1016/s0092-8674(00)81169-1 · Cited by 1,737
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,720
Reaching a Genetic and Molecular Understanding of Skeletal Development
Karsenty, G., & Wagner, E. F. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00157-0 · Cited by 1,611
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
T-Cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ.
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. (2000) · Nature · doi:10.1038/35046102 · Cited by 1,358
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signalingPreprint
Lomaga, M. A., Yeh, W., Sarosi, I., Duncan, G. S., Furlonger, C. L., Ho, A. P., Morony, S., Capparelli, C., Van, G. Y., Kaufman, S., et al. (1999) · Genes & Development · doi:10.1101/gad.13.8.1015 · Cited by 1,265
RANKL–RANK signaling in osteoclastogenesis and bone disease
Wada, T., Nakashima, T., Nishina, H., & Penninger, J. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.11.007 · Cited by 1,230
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro1
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Canonical Wnt/β-Catenin Signaling Prevents Osteoblasts from Differentiating into Chondrocytes
Hill, T. P., Später, D., Taketo, M. M., Birchmeier, W., & Hartmann, C. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.013 · Cited by 1,086
TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells
Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Requirement for NF-κB in osteoclast and B-cell development
Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997) · Genes & Development · doi:10.1101/gad.11.24.3482 · Cited by 996
Self-citation
Biology of RANK, RANKL, and osteoprotegerin
Boyce, B. F., & Xing, L. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2165 · Cited by 994
Self-citation
Osteopetrosis in mice lacking NF-κB1 and NF-κB2
Iotsova, V., Caamaño, J., Loy, J. K., Yang, Y., Lewin, A. C., & Bravo, R. (1997) · Nature Medicine · doi:10.1038/nm1197-1285 · Cited by 990
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 990
Bone and haematopoietic defects in mice lacking c-fos
Wang, Z., Ovitt, C. E., Grigoriadis, A. E., Möhle-Steinlein, U., Rüther, U., & Wagner, E. F. (1992) · Nature · doi:10.1038/360741a0 · Cited by 932
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050645 · Cited by 890
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis
Asagiri, M., Sato, K., Usami, T., Ochi, S., Nishina, H., Yoshida, H., Morita, I., Wagner, E. F., Mak, T. W., Serfling, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051150 · Cited by 849
Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S., & Ikeda, K. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.001 · Cited by 848
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis
Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., Iwata, T., Ohnishi, H., Matozaki, T., Kodama, T., et al. (2004) · Nature · doi:10.1038/nature02444 · Cited by 832
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Regulation of cancer cell migration and bone metastasis by RANKL.
Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., et al. (2006) · Nature · doi:10.1038/nature04524 · Cited by 796
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 777
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells
Kollet, Ó., Dar, A., Shivtiel, S., Kalinkovich, A., Lapid, K., Sztainberg, Y., Tesio, M., Samstein, R. M., Goichberg, P., Spiegel, A., et al. (2006) · Nature Medicine · doi:10.1038/nm1417 · Cited by 774
The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development.
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β
Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H. I., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. (2002) · Nature · doi:10.1038/416744a · Cited by 719
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice
Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K., Nakamura, K., Katsuki, M., Yamamoto, T. S., et al. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00265.x · Cited by 626
Nuclear Factor of Activated T-cells (NFAT) Rescues Osteoclastogenesis in Precursors Lacking c-Fos
Matsuo, K., Galson, D. L., Chen, Z., Peng, L., Laplace, C., Wang, K. Z. Q., Bachler, M. A., Amano, H., Aburatani, H., Ishikawa, H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313973200 · Cited by 570
v-ATPase V0 subunit d2–deficient mice exhibit impaired osteoclast fusion and increased bone formation
Lee, S.-H., Rho, J., Jeong, D., Sul, J., Kim, T. S., Kim, N., Kang, J.-S., Miyamoto, T. K., Suda, T., Lee, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1514 · Cited by 547
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo
Li, Y., Toraldo, G., Li, A., Yang, X., Zhang, H., Qian, W.-P., & Weitzmann, M. N. (2007) · Blood · doi:10.1182/blood-2006-07-037994 · Cited by 520
Osteopetrosis
Tolar, J., Teitelbaum, S. L., & Orchard, P. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040952 · Cited by 500
NFAT and Osterix cooperatively regulate bone formation
Koga, T., Matsui, Y., Asagiri, M., Kodama, T., Crombrugghe, B. D., Nakashima, K., & Takayanagi, H. (2005) · Nature Medicine · doi:10.1038/nm1270 · Cited by 497
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
Hughes, A. E., Ralston, S. H., Marken, J., Bell, C., Macpherson, H. K., Wallace, R. G. H., Hul, W. V., Whyte, M. P., Nakatsuka, K., Hovy, L., et al. (2000) · Nature Genetics · doi:10.1038/71667 · Cited by 484
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Collin‐Osdoby, P. (2004) · Circulation Research · doi:10.1161/01.res.0000149165.99974.12 · Cited by 474
IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation
Gao, Y., Grassi, F., Robbie‐Ryan, M., Terauchi, M., Page, K., Yang, X., Weitzmann, M. N., & Pacifici, R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30074 · Cited by 461
Osteoprotegerin Deficiency and Juvenile Paget's Disease
Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H., & Mumm, S. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013096 · Cited by 446
NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1
Yamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., Takeshita, S., Wagner, E. F., Noda, M., Matsuo, K., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610701200 · Cited by 414
Self-citation
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., Vargo-Gogola, T. C., Begtrup, J. L., Peterson, T. E., Fingleton, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.013 · Cited by 402
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
Sobacchi, C., Frattini, A., Guerrini, M. M., Abinun, M., Pangrazio, A., Susani, L., Bredius, R. G. M., Mancini, G. M. S., Cant, A. J., Bishop, N. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2076 · Cited by 389
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Osteoclast differentiation independent of the TRANCE–RANK–TRAF6 axis
Kim, N., Kadono, Y., Takami, M., Lee, J., Lee, S.-H., Okada, F., Kim, J. H., Kobayashi, T., Odgren, P. R., Nakano, H., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050978 · Cited by 374
Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts
Masuyama, R., Stockmans, I., Torrekens, S., Looveren, R. V., Maes, C., Carmeliet, P., Bouillon, R., & Carmeliet, G. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29463 · Cited by 332
Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD
Lewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319
Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE −/− Mice
Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304
Genetics, pathogenesis and complications of osteopetrosis
Fattore, A. D., Cappariello, A., & Teti, A. M. (2007) · Bone · doi:10.1016/j.bone.2007.08.029 · Cited by 286
Long-Term Treatment of Osteopetrosis with Recombinant Human Interferon Gamma
Key, L. L., Rodriguiz, R. M., Willi, S. M., Wright, N. M., Hatcher, H., Eyre, D. R., Curé, J. K., Griffin, P. P., & Ries, W. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322402 · Cited by 275
Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr (−/−) Mice
Morony, S., Tintut, Y., Zhang, Z., Cattley, R. C., Van, G., Dwyer, D., Stolina, M., Kostenuik, P. J., & Demer, L. L. (2008) · Circulation · doi:10.1161/circulationaha.107.707380 · Cited by 258
NOTCH1 Regulates Osteoclastogenesis Directly in Osteoclast Precursors and Indirectly via Osteoblast Lineage Cells
Bai, S., Kopan, R., Zou, W., Hilton, M. J., Ong, C., Long, F., Ross, F. P., & Teitelbaum, S. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707000200 · Cited by 237
Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand.
Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M., & Tanaka, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606656200 · Cited by 236
Osteoclast precursors, RANKL/RANK, and immunology
Xing, L., Schwarz, E. M., & Boyce, B. F. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00336.x · Cited by 236
Self-citation
Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans
Wesenbeeck, L. V., Odgren, P. R., Coxon, F. P., Frattini, A., Moens, P., Perdu, B., MacKay, C. A., Hul, E. V., Timmermans, J., Vanhoenacker, F. M. H. M., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30328 · Cited by 236
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
Chen, G., Sircar, K., Aprikian, A. G., Potti, A., Goltzman, D., & Rabbani, S. A. (2006) · Cancer · doi:10.1002/cncr.21978 · Cited by 229
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype
Cundy, T. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.18.2119 · Cited by 228
Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure
Ueland, T., Yndestad, A., Øie, E., Florholmen, G., Halvorsen, B. L., Frøland, S. S., Simonsen, S., Christensen, G., Gullestad, L. L., & Aukrust, P. (2005) · Circulation · doi:10.1161/01.cir.0000165119.62099.14 · Cited by 227
BMP2 Commitment to the Osteogenic Lineage Involves Activation of Runx2 by DLX3 and a Homeodomain Transcriptional Network
Hassan, M. Q., Tare, R. S., Lee, S. H., Mandeville, M., Morasso, M. I., Javed, A., van Wijnen, A. J., Stein, J. L., Stein, G. S., & Lian, J. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604508200 · Cited by 221
Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus*
Ikeda, T., Kasai, M., Utsuyama, M., & Hirokawa, K. (2001) · Endocrinology · doi:10.1210/endo.142.4.8070 · Cited by 215
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α–transgenic mice
Li, P., Schwarz, E. M., O’Keefe, R. J., Ma, L., Looney, R. J., Ritchlin, C. T., Boyce, B. F., & Xing, L. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11419 · Cited by 208
Self-citation
Contribution of Nuclear Factor of Activated T Cells c1 to the Transcriptional Control of Immunoreceptor Osteoclast-associated Receptor but Not Triggering Receptor Expressed by Myeloid Cells-2 during Osteoclastogenesis
Kim, Y., Sato, K., Asagiri, M., Morita, I., Soma, K., & Takayanagi, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505820200 · Cited by 199
Tumor Necrosis Factor-α Increases Circulating Osteoclast Precursor Numbers by Promoting Their Proliferation and Differentiation in the Bone Marrow through Up-regulation of c-Fms Expression
Yao, Z., Li, P., Zhang, Q., Schwarz, E. M., Keng, P., Arbini, A., Boyce, B. F., & Xing, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512624200 · Cited by 197
Self-citation
The RANK/RANKL/OPG triad in cancer-induced bone diseases
Dougall, W. C., & Chaisson, M. L. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9021-3 · Cited by 189
Mechanisms of Disease: the link between RANKL and arthritic bone disease
Schett, G. A., Hayer, S., Zwerina, J., Redlich, K., & Smolen, J. S. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0036 · Cited by 189
The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis
Wada, T., Nakashima, T., Oliveira-dos-Santos, A., Gasser, J. A., Hara, H., Schett, G. A., & Penninger, J. M. (2005) · Nature Medicine · doi:10.1038/nm1203 · Cited by 182
Runx2/Cbfa1: A Multifunctional Regulator of Bone Formation
Lian, J. B., & Stein, G. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453659 · Cited by 180
Signaling crosstalk between RANKL and interferons in osteoclast differentiation.
Takayanagi, H., Kim, S., & Taniguchi, T. (2002) · Arthritis Research · doi:10.1186/ar581 · Cited by 166
Increased lymphangiogenesis in joints of mice with inflammatory arthritis
Zhang, Q., Lu, Y., Proulx, S. T., Guo, R., Yao, Z., Schwarz, E. M., Boyce, B. F., & Xing, L. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2326 · Cited by 161
Self-citation
Role of Cbfa1 in osteoblast differentiation and function
Karsenty, G. (2000) · Seminars in Cell and Developmental Biology · doi:10.1006/scdb.2000.0188 · Cited by 159
Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation
ÉBAUD, D. T., Krieg, M., Berguer, D. G., Jacquet, A. F., Goy, J., & BURCKHARDT, P. (1996) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1996.00170.x · Cited by 154
Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis
Blair, J. M., Zhou, H., Seibel, M. J., & Dunstan, C. R. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0381 · Cited by 142
Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey, E. L., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.004 · Cited by 139
RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulationPreprint
Yang, S., & Li, Y. (2007) · Genes & Development · doi:10.1101/gad.1544107 · Cited by 138
Murine and Chicken Chondrocytes Regulate Osteoclastogenesis by Producing RANKL in Response to BMP2
Usui, M., Xing, L., Drissi, H., Zuscik, M. J., O’Keefe, R. J., Chen, D., & Boyce, B. F. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071025 · Cited by 129
Self-citation
Receptor activator of NF‐κB recruits multiple TRAF family adaptors and activates c‐Jun N‐terminal kinase
Kim, H.-H., Lee, D. E., Shin, J. N., Lee, Y. S., Jeon, Y. M., Chung, C.-H., Ni, J., Kwon, B. S., & Lee, Z. H. (1999) · FEBS Letters · doi:10.1016/s0014-5793(98)01731-1 · Cited by 125
NF-κB Specifically Activates BMP-2 Gene Expression in Growth Plate Chondrocytes in Vivo and in a Chondrocyte Cell Line in Vitro
Feng, J. Q., Xing, L., Zhang, J.-H., Zhao, M., Horn, D., Chan, J., Boyce, B. F., Harris, S. E., Mundy, G. R., & Chen, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212296200 · Cited by 125
Self-citation
EBF2 Regulates Osteoblast-Dependent Differentiation of Osteoclasts
Kieslinger, M., Roessler, S. K., Dobreva, G. D., Dorn, T., Croci, L., Erben, R. G., Consalez, G. G., & Grosschedl, R. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.10.009 · Cited by 120
Osteoclast Precursor Interaction with Bone Matrix Induces Osteoclast Formation Directly by an Interleukin-1-mediated Autocrine Mechanism
Yao, Z., Xing, L., Qin, C., Schwarz, E. M., & Boyce, B. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706415200 · Cited by 111
Self-citation
Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2
Kim, N., Kim, H.-J., Koo, B., Kwon, M.-C., Kim, Y.-W., Cho, Y., Yokota, Y., Penninger, J. M., & Kong, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1002-1013.2006 · Cited by 110
Runx2/Cbfa1 stimulation by retinoic acid is potentiated by BMP2 signaling through interaction with Smad1 on the collagen X promoter in chondrocytes
Drissi, H., Li, X., Sheu, T. J., Zuscik, M. J., Schwarz, E. M., Puzas, J. E., Rosier, R. N., & O’Keefe, R. J. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10677 · Cited by 94
VEGF-C, a Lymphatic Growth Factor, Is a RANKL Target Gene in Osteoclasts That Enhances Osteoclastic Bone Resorption through an Autocrine Mechanism
Zhang, Q., Guo, R., Lu, Y., Zhao, L., Zhou, Q., Schwarz, E. M., Huang, J. L., Chen, D., Jin, Z., Boyce, B. F., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708055200 · Cited by 89
Self-citation
The receptor activator of nuclear factor (NF)κB ligand (RANKL) is a new chemotactic factor for human monocytes
Breuil, V., Schmid‐Antomarchi, H., Schmid‐Alliana, A., Rezzonico, R., Euller‐Ziegler, L., & Rossi, B. (2003) · The FASEB Journal · doi:10.1096/fj.02-1188fje · Cited by 62
Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases
Boyce, B. F., Xing, L., Shakespeare, W. C., Wang, Y., Dalgarno, D. C., Iuliucci, J. D., & Sawyer, T. K. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s85.2.x · Cited by 53
Self-citation
IFN-γ Enhances Osteoclast Generation in Cultures of Peripheral Blood from Osteopetrotic Patients and Normalizes Superoxide Production
Madyastha, P. R., Yang, S., Ries, W. L., & Key, L. L. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/107999000414826 · Cited by 51
Osteoclasts and Integrins
Teitelbaum, S. L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.017 · Cited by 49
Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-κB in response to CpG-oligodeoxynucleotides in RAW 264.7 cells
Rhee, J. W., Lee, K., Sohn, W., Lee, Y., Jeon, O., Kwon, H., & Kim, D. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.05.003 · Cited by 49
Expression and function of RANK in human monocyte chemotaxis
Mosheimer, B. A., Kaneider, N. C., Feistritzer, C., Sturn, D. H., & Wiedermann, C. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20352 · Cited by 49
Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation
Yang, S., Chen, W., Stashenko, P., & Li, Y. (2007) · Journal of Cell Science · doi:10.1242/jcs.008300 · Cited by 44
Malignant Autosomal Recessive Osteopetrosis Caused by Spontaneous Mutation of Murine Rank
Kapur, R. P., Yao, Z., Iida, M. H., Clarke, C. M., Doggett, B., Xing, L., & Boyce, B. F. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040713 · Cited by 39
Self-citation
Receptor Activator of Nuclear Factor-κB Ligand-Induced Nuclear Factor of Activated T Cells (C1) Autoregulates Its Own Expression in Osteoclasts and Mediates the Up-Regulation of Tartrate-Resistant Acid Phosphatase
Fretz, J. A., Shevde, N. K., Singh, S., Darnay, B. G., & Pike, J. W. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0333 · Cited by 27
Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter
Chen, H., Gilbert, C. A., Hudson, J. A., Bolick, S. C. E., Wright, K. L., & Piskurich, J. F. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.04.026 · Cited by 25
Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy.
Sammartino, A., Cirillo, D., Mandato, V. D., Carlo, C. D., & Nappi, C. (2005) · PubMed · Cited by 19

Flagged first, then by citations

Research works printed but not linked: 9

Usui, 2007, J. Bone Miner. Res.
Wong, 2000, J. Bone Miner. Res., 15, 2293
Kearns, 2007, Endocr. Rev.
Hikita, 2006, J. Biol. Chem.
Bai, 2007, J. Biol. Chem.
Sammartino, 2005, J. Endocrinol. Invest., 28, 80
Fretz, 2007, Mol. Endocrinol.
Yao, 2006, JBMR, 21, S262
Guo, 2007, JBMR, 22, S30

Sorted by citations

International Journal of Molecular Sciences
Soni, N., Ross, A., Nookaew, I., Scheers, N., Gabrielsson, B., & Sandberg, A.-S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms · Cited by 10,136
Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells
Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J., & Cerri, P. S. (2015) · BioMed Research International · doi:10.1155/2015/421746 · Cited by 2,044
Osteoblast–osteoclast interactions
Chen, X., Wang, Z., Duan, N., Zhu, G., Schwarz, E. M., & Xie, C. L. (2017) · Connective Tissue Research · doi:10.1080/03008207.2017.1290085 · Cited by 905
Role of Inactivity in Chronic Diseases: Evolutionary Insight and Pathophysiological Mechanisms
Booth, F. W., Roberts, C. K., Thyfault, J. P., Ruegsegger, G. N., & Toedebusch, R. G. (2017) · Physiological Reviews · doi:10.1152/physrev.00019.2016 · Cited by 696
The Charcot Foot in Diabetes
Rogers, L. C., Frykberg, R. G., Armstrong, D. G., Boulton, A. J. M., EDMONDS, M. E., Van, G. H., Hartemann, A., Game, F. L., Jeffcoate, W. J., Jirkovská, A., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0844 · Cited by 597

See all 1,844

Authors: Boyce, B. F., & Xing, L.
Affiliations: University of Rochester Medicine (US)
Corresponding author: Boyce, Brendan F.
ORCID: Boyce, Brendan F.
Xing, Lianping
Venue: Archives of Biochemistry and Biophysics
Publisher: Elsevier BV
Published: 2008-05
Volume: 473
Issue: 2
Pages: 139-146
ISSN: 0003-9861 (ISSN-L)
DOI: 10.1016/j.abb.2008.03.018
PMC: PMC2413418
OpenAlex: W1975953388
Cited by: 1,844
References: 107
Citations by year: 2026: 107 · 2025: 132 · 2024: 149 · 2023: 127 · 2022: 145 · 2021: 166 · 2020: 141 · 2019: 122 · 2018: 94 · 2017: 106 · 2016: 71 · 2015: 92 · 2014: 76 · 2013: 73 · 2012: 69
FWCI: 4.48
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Archives of Biochemistry and Biophysics (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR049305, R01AR043510)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: RANK/RANKL/OPG system, bone remodeling, bone modeling, osteoclastogenesis, osteoclast activation, osteoclast survival, bone resorption, TNF superfamily, receptor activator of NF-kappaB, osteoprotegerin, bone turnover
MeSH terms: Animals, Bone Resorption, Cell Differentiation, Humans, Osteoclasts, Osteogenesis, Signal Transduction, Bone Remodeling, Mice, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functions of RANKL/RANK/OPG in bone modeling and remodeling

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks